Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04261621 · ClinicalTrials.gov registry record
Early Identification of SEPsis SIGNs in Emergency Department
A clinical trial of Sepsis and Infection, sponsored by BioMérieux.
- Completed
- Registry status
- 815
- Enrollment target
- 12
- Study locations
NCT04261621 is a study of Sepsis and Infection that has completed, run by BioMérieux. The registered enrollment target is 815 participants, below the 6,556-participant average among 90 other Sepsis trials with a reported enrollment target (88% lower). The trial reports 12 study locations across 5 states.
The verdict
NCT04261621, a study of Sepsis and Infection, has completed, sponsored by BioMérieux.
- COMPLETED
- Registry status
- 815 participants
- Enrollment target
- 12
- Study locations
Study Summary
Objective of SepSIGN project is to validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department. Targeted population is adult patients, freshly admitted at ED, with a suspected or confirmed infection.
Study Locations (12)
Other
- CH Henri Mondor Aurillac - Aurillac
- CHU Grenoble alpes - La Tronche
- CHU Dupuytren - Limoges
- Hopital Edouard Herriot, HCL - Lyon
- CH de Montauban - Montauban
- Hôpital Saint-Antoine AP-HP - Paris
- Hôpital Trousseau CHRU - Tours
- Centre Hospitalier Princesse Grace - Monaco
Colorado
- University of Colorado School of Medicine - Aurora
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Tennessee
- Vanderbilt University Medical Center - Nashville
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2022-05-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04261621
The ClinicalTrials.gov registry entry for NCT04261621 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 815 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,556-participant average among 90 other Sepsis trials with a reported enrollment target (88% lower). The listed sponsor is BioMérieux, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 0 interventions.
NCT04261621 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04261621 about?
NCT04261621 is a clinical study titled "Early Identification of SEPsis SIGNs in Emergency Department". Objective of SepSIGN project is to validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department. Targeted population is adult patients, freshly admitted at ED, with a suspected or confirmed infection.
What is the current status of trial NCT04261621?
This trial is currently completed. The enrollment target is 815 participants. The study started on 2020-07-06. Estimated completion is 2022-05-02.
What conditions does trial NCT04261621 study?
This clinical trial studies the following conditions: Sepsis, Infection.
Who is sponsoring clinical trial NCT04261621?
This trial is sponsored by BioMérieux, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04261621 being conducted?
This trial has 12 study locations across Colorado, Massachusetts, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.